跳至主要内容
临床试验/TCTR20210731004
TCTR20210731004招募中2 期

Immunogenicity and safety of the third dose COVID-19 vaccine in Thai population.

Chulabhorn Royal Academy0 个研究点目标入组 5,520 人开始时间: 2021年7月31日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
5,520

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. 18 years old or more 2. No history of a severe allergic reaction to the prior vaccine. 3. No fever nor history of fever within 14 days. 4. No symptoms of respiratory tract infection within 14 days. 5. Received two doses of COVID-19 vaccine for at least 3 months 6. sign informed consent to the study.

排除标准

  • 1. pregnancy. 2. lactation. 3. History of SARS-CoV-2 infection

研究者

相似试验

招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine via intradermal compare with intramuscular administration (Randomized controlled trial)The immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers.COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, Sinopharm
TCTR20210731003Chulabhorn Royal Academy960
Unknown
3 期
Safety and immunogenicity of the third COVID-19 vaccines booster dose in children (12-18 years) with completed 2 doses as recommended by the ministry of public healthHealth adolescentsCOVID-19, booster, vaccine
TCTR20221215006Chulalongkorn University320
进行中(未招募)
不适用
Immunogenicity of the 3rd COVID-19 vaccine dose in Thai healthcare workers at Bamrasnaradura Infectious Diseases InstituteHealthcare workers who received two doses of SinovacCOVID-19 VaccineSARS-CoV-2AntibodyHealthcare WorkersAstraZenecaPfizer
TCTR20211005001ational Research Council of Thailand (NRCT)170
已完成
Unknown
Immune response to a third COVID-19 vaccine dose in people with multiple sclerosis receiving B cell-depleting therapyImmunosuppressionCOVID-19 vaccinationNeurological - Multiple sclerosisInfection - Other infectious diseasesMultiple Sclerosis
ACTRN12623001249640Royal Adelaide Hospital53
招募中
不适用
Pattern of antibody response after 3rd dose of COVID-19 vaccine booster among healthy volunteers.Healthy volunteerCOVID-19 Vaccinesadministration and dosageimmunology
TCTR20210831002akornping Hospital180